SG Americas Securities
INZY

SG Americas Securities’s Inozyme Pharma INZY Stock Holding History

SG Americas Securities’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,161
Closed -$15K – 3254
2025
Q1 		$15K Buy
16,161
+227
+1% +$315 ﹤0.01% 3396
2024
Q4 		$44K Buy
15,934
+477
+3% +$1.81K ﹤0.01% 2928
2024
Q3 		$81K Buy
+15,457
New +$80.2K ﹤0.01% 3131
2024
Q2 		– Sell
-13,926
Closed -$107K – 3059
2024
Q1 		$107K Sell
13,926
-7,310
-34% -$40.1K ﹤0.01% 2505
2023
Q4 		$90K Buy
21,236
+6,784
+47% +$24.1K ﹤0.01% 2802
2023
Q3 		$61K Buy
+14,452
New +$73.5K ﹤0.01% 2896
2021
Q4 		– Sell
-11,611
Closed -$135K – 3589
2021
Q3 		$135K Buy
+11,611
New +$181K ﹤0.01% 3501

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

SG Americas Securities's INZY Position: Q2 2025 in Review

SG Americas Securities sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 16,161 shares — an estimated $15K sold.

SG Americas Securities first reported a position in INZY in Q3 2021 and held it in 7 quarters. The position peaked at $135K in Q3 2021. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • SG Americas Securities reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 16,161 Inozyme Pharma shares in Q2 2025, an estimated $15K.
  • SG Americas Securities first reported a position in Inozyme Pharma in Q3 2021 and held it in 7 quarters.
  • SG Americas Securities's Inozyme Pharma position peaked at $135K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.